In 2015, the Temprano and START trials provided evidence supporting early ART initiation, prompting the WHO to recommend ART at diagnosis for HIV-infected persons. Our objective was to project the clinical and economic outcomes, cost-effectiveness, and 5yr budget impact of immediate ART initiation in Côte d’Ivoire, the setting of Temprano.
We used a mathematical model of HIV (CEPAC-I), informed by the Temprano trial, to assess three ART initiation criteria in Côte d’Ivoire: 1) CD4 count <350/μL; 2) CD4 count <500/μL; and 3) Immediate ART. We reported outcomes from the payor perspective for the entire HIV-infected population currently in care in Côte d’Ivoire (All-in-care, mean CD4 259/μL; 170,000 persons) and for only those in care with CD4 counts >500 cells/µL (>500/µL-in-care, mean CD4: 666/uL; 22,000 persons). We assumed viral load-dependent transmission rates (0.16-9.03/100PY). ART 48-week efficacy was 80% and adherence-dependent loss to follow-up rates were 1.9-13%/month. 1st- and 2nd-line ART costs were $122 and $391/year. Outcomes included transmitted HIV cases, life expectancy in life-years (LY), 10yr incremental cost-effectiveness ratios (ICERs), and 5yr budget impact. We labeled a strategy ‘cost-effective’ if its ICER, in $/year of life saved (YLS), was less than the annual per capita GDP in Côte d’Ivoire ($1,530). We conducted extensive sensitivity analyses to assess the impact of parameter uncertainty on our findings.
For All-in-care, Immediate ART decreased 10-year transmissions from 93,900 to 84,800 (-9.7%) compared to ART<350/µL and increased life expectancy by 17,000 LYs over 10 years, yielding an ICER of $300/YLS (<0.25x per capita GDP). Immediate ART increased total 5yr costs from $515.5M to $523.4M (+1.4%) compared to ART<350/µL. Increasing mean CD4 at linkage to care to 500/µl and varying transmission rates over their 95% confidence interval, the 5yr cost difference for Immediate ART compared to ART<350/µL ranged from -11.1% to +3.1%. For the >500/µL-in-care, Immediate ART was cost-saving over 10yr, with small increases in 5yr costs (+2.3%). Cost-effectiveness and budget impact findings were most sensitive to 1st-line ART cost.
In Côte d’Ivoire, Immediate ART compared to later initiation reduces HIV transmissions, increases survival, and is very cost-effective, all with modest increase in program costs. Immediate ART initiation should be the standard of care in Côte d’Ivoire and similar settings.